Get started
PFIZER INCPFIZER INCPFIZER INC

PFIZER INC

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

PFE trade ideas

$PFE - H&S on 30mYet another bearish signal. On the 30m timeframe we see a Head & Shoulder pattern formed suggesting a bearish reversal. The neckline is a trend line that is drawn across the intervening lows and should be horizontal or upward sloping to the breakout area. As you can see we closed below the neckline suggesting a breakout confirmation with above average volume. To get your target you measure the distance between the low of the first shoulder to the high of the head. Then subtract that amount on the neckline of the breakout. My PT is around $45. Remember, MM’s can easily drop it lower so be aware of the trend so you don’t buy in too early. This shouldn’t happen all in one day even though it is possible. My prediction tomorrow is that it makes another lower high around $49.50 to trap more bulls into Friday and next week. Overall I’m still very bullish on this stock but it need this correction before we can pass $52. There are lots of eyes on PFE and a lot of people are waiting on an entry at $45, so it may bounce pretty quickly there. But we will see. LMK what you think!
NYSE:PFEShort
by DarthTrador
3
$PFE - Shooting StarOn the daily timeframe we can see what looks like to be a Shooting Star candlestick which indicates the end of an uptrend and start of a downtrend. PFE has been going up for about a month straight now and has been due for a major correction along with the market as a whole. However, vaccine stocks have been on everyone’s radar as the Delta V has been on everyone’s mind. FDA approval being speculated on early September, but could easily be pushed early to end of Aug which could result to a sell the news type event. However at the same time we have big buyers stepping in but does that mean they know something we don’t or are they here for the short term? I learned that speculation turns into emotional trading so I am just going to follow the trend. But I’d be lying right now if I didn’t say that candlestick worries me. For now I am short term bearish. I can see a pull back all the way to the $45 levels. For tomorrow I can see a bounce at the $48.30 levels. We’ll see! LMK what you think!
NYSE:PFEShort
by DarthTrador
2
$PFE - ABC Correction Pt 2.Last time I charted $PFE I was wrong about wave (C) going lower but we still had a good entry to ATH we see now. Today we completed Wave (5) from the previous 2 cycles now about to be on its 3rd. PFE has been respectin EW theory pretty well so far. According to EW we should see some type of ABC correction. Mid day PFE tanked hard and fast which completed corrective Wave (A). Then PFE slowly recovered back to ATH’s completing corrective wave (B). However that last candle stick seems very sus to me. If you look at PFE for the past couple weeks we can see that with every run up we had a pullback specifically on Wednesday. Tomorrow is Wednesday (8/18) and if it should still follow trend we can anticipate a pullback coming up. That final candle seemed like a bull trap to me with that long wick touching ATH, tricking bulls to think it will run up again tomorrow. However I could be wrong and PFE could rocket at the bell. (This is less likely) I think we touch the $48.50 area and then slowly recovery to $50 EOD then maybe touching $52 EOW. LMK what you think!
NYSE:PFELong
by DarthTrador
2
PFE STRONG AF: All indicators point to continued strong uptrend I REALLY liking PFE rn for long. Here is why ~ Today it not only crossed the VWAP, but it broke the 75th percentile indicating upcoming higher highs. ~ Not only is it riding above the VWAP rn, but there is a nice gap between the price action and SMMA indicating a continued uptrend ~ Price action > 30 EMA > 200 EMA and there is a nice gap between both EMAs. this setup signifies a strong uptrend and an excellent long entry. (especially paired with the fact that the VWAP was crossed) ~ We are maintaining a strong uptrend already on the 50 MA and hourly chart with the 50 MA being a solid support line. I am swinging a PFE call atm (ITM) as PFE is about to be overbought but is not there yet. I believe we may see another test of 50.50 before the pullback. I am hoping we can break it, but if not 50.50 will become a great support zone once we do pass it. I am planning on selling at 50-60 percent profit ( I am at 49 percent rn) and am going to reenter when we retest the VWAP.
NYSE:PFELong
by MathewPiedoux
Pfizer here we go! Holding while price is green. 🚀🚀🚀Stocks trend. A lot. Much more than Forex. Pfizer is going parabolic while breaking all time high and $50, this could be the start of a big trend, or it might not. Let's look at a few examples starting with Pfizer. Clearly we see how with stocks we can make big multiples of our risk. Like 25R in stocks versus 10R in Forex (for example, reality is probably close to that) Zooming in the little impulses: I don't know how many "casuals" are interested in Pfizer, but it is a word billions of people know. We can look at Tesla & PonziStop: How about another one just to illustrate? So the question is, how to hold on but without giving back all profits? 1 solution is sell half once a stop is reached keep half with a much wider stop. Smooths out the PnL. And this is probably what I'll do. On a longer TF I'd look to add, here this is all a short term play, expecting the stock to go parabolic. I am at exactly 5 times my risk (counting spreads) as of writting this. Hasn't even been 2 weeks yet. Talk about a monster. This risk a monster correction too. Hopefully it warns before.
NYSE:PFELong
by MrRenev
4
PFE Uptrend Strong Waiting for pullback to 50 MAPfizer is in a strong uptrend and its hourly keeps coming back to the 50 MA. Each time it has come back to the 50 MA, it has met at a support area. I believe we may see PFE run a bit higher before it returns to the 50 MA as the RSI is undecided (although slightly on a decline). The hourly wicks also do not show any signs of a pullback yet, which supports this idea of a new ATH in the making. I am holding my PFE call until I see some more resistance, but once the tide changes for short term bears I will sell and wait until PFE pulls back to 48.50 (and closes green after touching the 50 MA) before entering calls.
NYSE:PFE
by MathewPiedoux
1
The Story of Pfizer: The Big Swing - A 22% WinnerOffshore equities is the name of the game. Let me say that again: OFFSHORE EQUITIES IS THE NAME OF THE GAME. Despite the US being expensive from a valuation perspective, there are always an TRADING opportunities for clients to make money. From small to mid, to large to mega-cap. Across sectors and industries as well as thematic opportunities, where momentum can run for days and weeks on end. For the week starting 05 July, we included Pfizer in our report, with the following comment: "What’s Happening In Healthcare? Pfizer (PFE, 39.73) - In April we discussed the healthcare sector, where we noted some attractive medium term setups. Have a look at a PFE where we note a low volume consolidation while the price trades below a 32-month downward trend. Figures in USD." Over the next for weeks the stock broke to the upside to take a momentum run not seen in a while. As at this week's peak, the name was higher by 22% over the 5-week period. Well done to all who managed to catch this!!! What's next? Where is the next big swing? Which sector? Which theme? Is your broker helping you find these opportunities, or is he leaving you scratching your head while he collects his monthly fees? As a researcher/analyst, it's my goal to find opportunities that make a difference to client accounts, helping them benefit from market moves and guiding them via my lens and perspective of markets. If you would like to gain real-time access to these opportunities, get in touch with me today.
NYSE:PFE
by LD_Perspectives
PFIZER INC.:FUNDAMENTAL ANALYSIS+PRICE ACTION|NEXT TARGET|LONG🔔Earlier this month, Pfizer announced promising first-line results from a Phase 2b/3 trial testing the JAK inhibitor ritecitinib for the treatment of alopecia(baldness), suggesting that the drug could finally be approved to treat this autoimmune disease that causes hair loss. But as Jeff Little noted, "The FDA has recently been paying increased attention to the potential side effects of JAK inhibitors, which belong to a family of drugs called DMARDs (disease-modifying anti-rheumatic drugs)." Let's look at the results of the study, what the FDA's concerns mean for this drug and others like it, and whether pharmaceutical giant Pfizer has a chance to make a name for itself in the growing global market for alopecia medications. Pfizer's phase 2b/3 study of the drug ritlecitinib examined the drug's effect on alopecia treatment in a randomized clinical trial involving 719 patients. These patients were 12 years of age or older, had 50% or more scalp hair loss (as measured by the Severity of Alopecia Tool scale, or SALT), and had experienced a current episode lasting six months to 10 years. Pfizer remarked that a clinically meaningful proportion of patients who received 30 mg or 50 mg of ritlecitinib daily achieved less than 20% head hair loss on the SALT scale after 24 weeks of treatment opposed to placebo, consistent with the study's primary efficacy endpoint of improved head hair regrowth. According to Pfizer, the scientific basis for ritlecitinib is that the drug stops the body's immune system from attacking hair follicles, which is thought to contribute to hair loss in patients with alopecia. Despite the study's encouraging results, it's worth noting that ritlecitinib's path to FDA approval for the alopecia indication (or for vitiligo, rheumatoid arthritis, Crohn's disease, and ulcerative colitis, for that matter) will be even more thorough than usual because of its special class of drugs. Ritlecitinib belongs to the class of Janus kinase inhibitors, or JAK inhibitors, which have been under scrutiny by the FDA lately. As per Fierce Pharma, a post-marketing study of Pfizer's JAK-inhibitor Xeljanz revealed serious heart and cancer side effects when the study results were published at the beginning of the year. This urged the FDA to delay the potential approval of the JAK inhibitor back in February while the agency investigates further. Xeljanz was first approved by the FDA in 2012 to treat rheumatoid arthritis, or RA, an autoimmune disease that can cause joint pain and damage throughout the body. The drug was also approved by the FDA in 2017 to treat psoriatic arthritis and in 2018 to treat ulcerative colitis. Although no serious adverse cardiac events or deaths were reported in Pfizer's study of ritlecitinib, it is in this class of drugs. As a result, its future remains very uncertain. If the JAK inhibitor class ultimately withstands increased regulatory scrutiny and the efficacy of ritlecitinib safely treating alopecia persists, the drug could provide a reliable revenue stream for Pfizer. To support this thesis, let's take a look at the global alopecia market and its growth forecast. Pointing to the "increasing prevalence of hair loss" as well as "technological advances in alopecia treatment," Grand View Research believes that the total global alopecia market will grow at an annual rate of 8.1% from $7.6 billion in 2020 to $14.2 billion by 2028. If the alopecia market stays at 35.2% of the total global alopecia market as it was in 2020, Pfizer's total addressable market in this area will be $5 billion by 2028. Given that Pfizer will likely face competition from Concert Pharmaceuticals' JAK inhibitor CTP-543 (first Phase 3 results not expected until 2022) and Eli Lilly and Incyte's JAK inhibitor baricitinib (currently awaiting FDA decision) when it enters the alopecia market, a fragmented market share of 15% is realistic. This would result in $750 million in annual revenue associated with the alopecia drug indications by 2028, which is about 1% of Pfizer's projected 2021 revenue of $78-80 billion. As questions arise about whether JAK inhibitors such as ritlecitinib will be able to gain regulatory approval in the future, it is worth noting that Pfizer does not significantly necessitate that approval to boost earnings in the coming years. In addition to the BNT162b2 COVID-19 vaccine, developed with German company BioNTech, Pfizer also expects to be able to apply for approval in the fourth quarter of this year for the emergency use of the oral antiviral drug COVID-19, known as PF-07321332. Keith Speights thinks this could be a real blockbuster given the huge addressable market, especially since Pfizer won't have to share the profits from oral therapy as it does with BioNTech in the case of BNT162b2. In addition to COVID-19, Pfizer's oncology biosimilars (Ruxience, Zirabev, and Retacrit) tripled their combined sales from $107 million in the second quarter of 2020 to $352 million in the second quarter of 2021, another good catalyst for growth going forward. Nearly half of Pfizer's projected sales this year will come from the $33.5 billion the company expects from its BNT162b2 COVID-19 vaccine (after splitting revenue with a partner, BioNTech). This is based on the 2.1 billion doses the company estimates will be delivered this year. Given sales of the breast cancer drug Ibrance ($1.4 billion through Q2 2021) and the anticoagulant Eliquis ($1.5 billion through Q2 2021), we can assume that these two drugs will also bring in about $3 billion each.
NYSE:PFELong
by FOREXN1
6